Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Recent Advances in Nanotechnology-based Therapeutics for Osteoarthritis: Addressing Limitations of Conventional Treatments.

Created on 03 Nov 2026

Authors

Sejal Sharma, Parina Gill, Rajni Bala, Rishi Kumar, Rhythm Sood

Published in

Recent advances in inflammation & allergy drug discovery. Oct 20, 2026. Epub Oct 20, 2026.

Abstract

Osteoarthritis (OA) is a heterogeneous whole-joint disorder for which current care mainly reduces pain and improves function without reliably modifying structural progression.
This narrative review used a structured search of PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar through August 2026. English-language peer-reviewed studies and regulatory guidance addressing OA mechanisms, nanocarrier performance, safety, or clinical translation were included; duplicate, non-scholarly, and non-OA reports were excluded. Evidence was synthesized by carrier, biological target, and development stage, without metaanalysis.
Liposomes, transferosomes, ethosomes, polymeric nanoparticles, lipid nanoparticles, micelles, extracellular vesicles, nanozymes, and stimuli-responsive systems can improve local exposure and protect small-molecule or nucleic-acid cargos. Most OA-specific evidence remains in vitro or animal-based, and no nanotechnology-enabled disease-modifying OA drug (DMOAD) has regulatory approval. Artificial intelligence (AI) may assist imaging, trial enrichment, formulation optimization, and treatment monitoring, but prospective validation is limited.
Nanotechnology can integrate joint retention, tissue targeting, responsive release, imaging, and combination therapy, but added functionality increases manufacturing, safety, cost, and regulatory burdens.
Biodegradable polymeric or lipid carriers combined with injectable depots appear closest to translation because they balance cargo flexibility, joint residence, and manufacturing precedent; progress requires reproducible production, long-term biodistribution data, phenotype- aware trials, and endpoints linking structural change with patient benefit.

PMID:
42973327
Bibliographic data and abstract were imported from PubMed on 03 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement